Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

The team unveiled a carbon nanotube (CNT) transistor chip that processes data not just in ones and zeros, but also a third state, enabling computations to occur faster and with less energy.

Let's explore the potentials of these low-cap meme coins that could propel them to 10x investors' portfolios. Shiba Inu (SHIB): The Meme Coin That's Turning Investors Into Millionaires Shiba Inu ...

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Popcorn is one of my all-time favorite snacks, especially now that I have to eat gluten-free. It's a quick way to fill me up without having to worry about what's in it. Whether it's buttery movie ...

10x Genomics has a fifty-two week low of $9.77 and a fifty-two week high of $45.60. The firm’s 50 day moving average price is $13.90 and its 200 day moving average price is $16.67. Get 10x ...

Here’s how it works. Now, this is a pretty early refresh for the iPad Air, considering it was upgraded to the M2 chip and a refreshed design on May 7, 2024. Still, it’s clearly popular within ...

Barry L. Ayers, 82, of Fredericksburg, rural Martinsburg, died Sunday. He was born in Martinsburg, son of the late Glenn and Thelma (Brumbaugh) Ayers. Surviving are his wife, Lois; daughters ...

During a press conference at the White House Monday, US President Donald Trump and Taiwan Semiconductor Manufacturing Company (TSMC), the world's largest chip manufacturer, announced that TSMC ...

March 3 (UPI) --President Donald Trump on Monday met with the chief of one of the world's biggest semiconductor chip producers amid talk of a new hundred billion-dollar U.S. investment.

PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.